This study is currently not recruiting participants.

A Phase Ib Open-label multi-centre study to assess the safety tolerability pharmacokinetics and anti-tumour activity of AZD1775 Monotherapy in Patients with Advanced solid tumours.

Study on Investigational Drug for Advanced Solid Tumors

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

The purpose of this study is to determine how patients with advanced solid tumors that received previous cancer treatment will respond to the investigational drug AZD1775 when given alone.

Detailed description of study

The purpose of this study is to determine how patients with advanced solid tumors that received previous cancer treatment will respond to the investigation drug when given alone.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Advanced solid tumors
  • Age: 18 years - 100 years
  • Gender: All

This study investigates how patients with advanced solid tumors, who have already received cancer treatment, respond to an investigational medication when it is given alone. Advanced solid tumors are cancers that have spread or are not responding to standard treatments.

Participants will receive the investigational medication without any other cancer treatments. The study will monitor how the tumors react to this treatment and assess any side effects experienced by the participants.

  • Who can participate: Individuals aged 18 and older with advanced solid tumors who have previously undergone cancer treatment are eligible for this study.
  • Study details: Participants will take the investigational medication alone, and their response will be closely monitored. The study aims to understand the effects of the medication on tumor growth and any side effects.
Updated on 19 Feb 2024. Study ID: 1508583961

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team